瑞舒伐他汀治疗冠心病的临床效果研究

目的探讨瑞舒伐他汀治疗冠心病患者的临床效果。方法 120例冠心病患者,按照入院时间分为观察组与对照组,各60例。对照组单纯采用复方丹参滴丸治疗,观察组采用瑞舒伐他汀联合复方丹参滴丸进行治疗。记录比较两组患者不良反应发生情况,治疗前及治疗后30 d后的超敏C反应蛋白(hs-CRP)、白细胞介素-6 (IL-6)、肿瘤坏死因子α(TNF-α)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平。结果观察组治疗总有效率96.67%高于对照组的86.67%,差异有统计学意义(P<0.05)。治疗30 d后,观察组的TC、TG、LDL-C水平分别为(3.64±0.42)、(1.31±0.16)、(1.39±0.42)mmol/L,均低于对照组的(4.52±0.48)、(1.68±0.21)、(2.21±1.21)mmol/L,差异有统计学意义(P<0.05)。治疗30 d后,观察组的hs-CRP、TNF-α、IL-6水平分别为(10.21±3.28)mg/L、(4.28±1.41)pg/ml、(139.77±22.21)pg/ml,均低于对照组的(12.28±5.62)mg/L、(5.16±1.47)pg/ml、(161.72±29.62)pg/ml,差异有统计学意义(P<0.05)。结论采用瑞舒伐他汀治疗冠心病能够较好改善患者的临床症状,降低患者的血脂水平、炎症因子水平,继而改善患者的预后,治疗效果显著。

Study on clinical effect of rosuvastatin in the treatment of coronary heart disease

Objective To discuss the clinical effect of rosuvastatin in the treatment of coronary heart disease. Methods A total of 120 coronary heart disease patients were divided into observation group and control group by admission order, with 60 cases in each group. The control group was treated by compound Danshen dripping pills, and the observation group was treated by rosuvastatin combined with compound Danshen dripping pills. The occurrence of adverse reactions, the levels of high sensitive C-reactive protein(hs-CRP), interleukin-6(IL-6), tumor necrosis factor α(TNF-α), total cholesterol(TC), triacylglycerol(TG), low density lipoprotein chol before treatment and 30 d after treatment were recorded and compared between the two groups. Results The total effective rate of treatment 96.67% of the observation group was higher than that of the control group 86.67%, and the difference was statistically significant(P<0.05). 30 d after treatment, the levels of TC, TG and LDL-C of the observation group were(3.64±0.42),(1.31±0.16) and(1.39±0.42) mmol/L respectively, which were lower than those of the control group(4.52±0.48),(1.68±0.21) and(2.21±1.21) mmol/L, and the difference was statistically significant(P<0.05). 30 d after treatment, the levels of hs-CRP, TNF-α and IL-6 of the observation group were(10.21±3.28) mg/L,(4.28±1.41) pg/ml and(139.77±22.21) pg/ml respectively, which were lower than those of the control group(12.28±5.62) mg/L,(5.16±1.47) pg/ml and(161.72±29.62) pg/ml, and the difference was statistically significant(P<0.05). Conclusion Rosuvastatin shows remarkable therapeutic effect for patients with coronary heart disease, which can improve the clinical symptoms of patients, reduce the level of blood lipid and inflammatory factors, and then improve the prognosis of patients.